News | May 21, 2010

First Successful Deployment of New Transcatheter Mitral Valve Disclosed

May 21, 2010 – The first successful transcatheter mitral valve implantation (TMVI) for a new mitral valve technology will be highlighted at the EuroPCR 2010 scientific meeting in Paris. A proprietary transcatheter delivery system was used to successfully deliver the valve in the porcine model.

Arshad Quadri, M.D., co-founder, chairman and chief medical officer of Cardiaq Valve Technologies (CVT), will present information about the new self-conforming and self-anchoring valve Tuesday, May 25. The presentation will report six major outcomes of an acute in vivo study of the TMVI system:

• Accurate positioning of the implanted valve relative to the mitral valve annulus
• Secure anchoring of the implanted valve to the mitral anatomy without relying on radial force
• Preservation of the subvalvular apparatus
• Conformance of the implanted valve to the mitral annulus to prevent paravalvular leaks
• Confirmation of a clear, unobstructed left ventricular outflow tract (LVOT)
• The successful delivery and deployment of the implant through an antegrade, transvenous, transseptal, catheter-based approach

Other companies have published results for minimally invasive, transapical approaches to mitral valve replacement. However, CVT believes this is the first time anyone has successfully deployed a mitral valve through a transvenous, transseptal, catheter-based approach.

“Given the enormous unmet clinical need for the overwhelming majority of patients who suffer from mitral regurgitation (MR), we are extremely pleased by this significant milestone,” Quadri said. “The vast majority of MR patients suffer from functional MR and many are too sick to undergo heart valve surgery. In addition, surgical repair is largely ineffective with these patients, as the recurrent rate of MR after repair is about 20 percent. With CVT’s TMVI approach, it appears that easy access along with precise placement may permit a truly interventional or nonsurgical procedure to replace a mitral valve.”

The CVT procedure is designed to be performed in a cardiac catheterization laboratory similar to angioplasty or stenting, resulting in less trauma to the patient and substantial cost-savings to the healthcare system.

For more information:

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Overlay Init